Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VV-GMCSF-Lact in Recurrent/Refractory Metastatic Breast Cancer
NCT05376527Phase 1Completed
- Start
- May 2022
- Primary completion
- Feb 2025
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of double recombinant vaccinia virus VV-GMCSF-Lact in breast cancer. Primary endpoints: Safety Parameters at 90 days and Number of Participants With Dose-limiting Toxicity at 14 days. Started May 2022; status: completed.
02
Drugs
double recombinant vaccinia virus VV-GMCSF-Lact
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05376527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05376527.